CA2683444A1 - Administration of carboline derivatives useful in the treatment of cancer and other diseases - Google Patents

Administration of carboline derivatives useful in the treatment of cancer and other diseases Download PDF

Info

Publication number
CA2683444A1
CA2683444A1 CA002683444A CA2683444A CA2683444A1 CA 2683444 A1 CA2683444 A1 CA 2683444A1 CA 002683444 A CA002683444 A CA 002683444A CA 2683444 A CA2683444 A CA 2683444A CA 2683444 A1 CA2683444 A1 CA 2683444A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
alkoxy
aryl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002683444A
Other languages
English (en)
French (fr)
Inventor
Liangxian Cao
Samit Hirawat
Langdon Miller
Gary L. Elfring
Maria L. Weetall
Thomas Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2683444A1 publication Critical patent/CA2683444A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002683444A 2007-04-13 2008-04-12 Administration of carboline derivatives useful in the treatment of cancer and other diseases Abandoned CA2683444A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91161207P 2007-04-13 2007-04-13
US60/911,612 2007-04-13
PCT/US2008/004809 WO2008127714A1 (en) 2007-04-13 2008-04-12 Administration of carboline derivatives useful in the treatment of cancer and other diseases

Publications (1)

Publication Number Publication Date
CA2683444A1 true CA2683444A1 (en) 2008-10-23

Family

ID=39618825

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002683444A Abandoned CA2683444A1 (en) 2007-04-13 2008-04-12 Administration of carboline derivatives useful in the treatment of cancer and other diseases

Country Status (6)

Country Link
US (1) US20100158858A1 (enExample)
EP (1) EP2139476A1 (enExample)
JP (1) JP2010523682A (enExample)
AU (1) AU2008239598A1 (enExample)
CA (1) CA2683444A1 (enExample)
WO (1) WO2008127714A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7601840B2 (en) * 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP2730282A1 (en) * 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2010138659A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
HUE052510T2 (hu) * 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
WO2010138695A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138685A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
WO2010138644A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Processes for the preparation of substituted tetrahydro beta-carbolines
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
AP2015008858A0 (en) 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
US10307406B2 (en) 2013-08-31 2019-06-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor
US11427600B2 (en) * 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
EP3554494A4 (en) 2016-12-19 2021-02-17 Cellixbio Private Limited INFLAMMATION TREATMENT COMPOSITIONS AND METHODS
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
CA3107737A1 (en) * 2018-08-03 2020-02-06 Ptc Therapeutics, Inc. Bioavailable oral dosage forms
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
WO2020150326A1 (en) 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US254878A (en) * 1882-03-14 Train-boat
US272759A (en) * 1883-02-20 Desk-top
US64683A (en) * 1867-05-14 mason and joseph messinger
US282849A (en) * 1883-08-07 Fruit-jar
US40527A (en) * 1863-11-03 Improvement in cooking-stoves
EP1322333A2 (en) * 2000-08-09 2003-07-02 Pharmacia Italia S.p.A. Composition for combined use of aromatase inhibitors
MXPA03007142A (es) * 2001-02-12 2004-05-24 Lilly Icos Llc Derivados de carbolina.
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer

Also Published As

Publication number Publication date
AU2008239598A1 (en) 2008-10-23
US20100158858A1 (en) 2010-06-24
EP2139476A1 (en) 2010-01-06
WO2008127714A1 (en) 2008-10-23
JP2010523682A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
US20100158858A1 (en) Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2008127715A1 (en) Carboline derivatives useful in the treatment of cancer and other diseases
CA2559408C (en) Carboline derivatives useful in the inhibition of angiogenesis
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
US11447461B2 (en) Benzothiophene-based selective estrogen receptor downregulators
US8372860B2 (en) Carboline derivatives useful in the inhibition of angiogenesis
TW201018672A (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders
TW201835064A (zh) 苯并噻吩雌激素受體調節劑
CA3233554A1 (en) Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor
US20190248780A1 (en) Benzothiophene-based selective mixed estrogen receptor downregulators
JP2006070032A (ja) 抗血管形成薬剤組成物
WO2018005444A2 (en) Methods for treating cancer
PT1885187E (pt) Métodos para o tratamento de cancro resistente a fármacos
JP2024123152A (ja) 化学療法難治性がんの治療のための新しい併用薬方法
WO2018102824A1 (en) Methods for treating neurodegenerative disease
HK1262188A1 (en) Benzothiophene-based selective estrogen receptor downregulators

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140414